1948: Alfa Wassermann was founded in Bologna by Dr Marino Golinelli on 24 January.
1960: The research laboratories were established. Since then Alfa Wassermann has developed many innovative products which have greatly contributed to the growth of the company.
1970-1990: In addition to research activities, the company made major investments in technology, which achieved high levels of quality and production innovation at its Alanno (PE) plant.
1989: The International Division was established together with a network of distributors and licensees in more than sixty countries around the world.
2004: The US Food and Drug Administration (FDA) approved the active ingredient Rifaximin-α on 26 May. This pharmaceutical product, developed in Alfa Wassermann's own research laboratories, is sold in the U.S. market under the brand name Xifaxan.
2012: During the first decade of 2000, new European and non-European companies joined the Alfa Wassermann group.
2015: Alfasigma is the result of the merger of Alfa Wassermann and Sigma-Tau, two of the most important pharmaceutical groups in Italy.
Alfasigma takes its place among the five top operators in the Italian pharmaceutical market, both in prescription and over-the-counter products, with a turnover of more than 900 million euros.
Alfasigma operates directly in 18 countries, including the USA, China, Russia and various European countries, employing around 2800, of whom, 1840 are in Italy and 960 are based in branches abroad. The operational bases in Italy will be: Milan, Bologna, Pomezia, Alanno and Sermoneta. The last three are production sites equipped with the very latest cutting-edge technologies.
Alfasigma, thanks to its extensive portfolio of products, commands a leading position in the Italian market in the fields of orthopaedics-rheumatology, the cardiometabolic area, diabetology and gastroenterology.
Alfasigma invests a significant share of its turnover in R&D in order to identify therapies that can offer new treatment opportunities for those who have to cope with illnesses with high clinical and social impact. A significant outcome of this work has been Rifaximin-α (Normix), a product used for various gastroenterological disorders that is marketed in 39 countries around the world. In the USA, under the brand name Xifaxan, it is one of the leading 50 products in terms of turnover.
The R&D Centre in Pomezia (Rome) concentrates mainly in immuno-oncology, specifically through the study and development of proprietary biotechnology platforms aimed at innovative, targeted therapies.